Ambrx Biopharma Inc
AMAM
AMAM was delisted on the 6th of March, 2024.
14 hedge funds and large institutions have $45.4M invested in Ambrx Biopharma Inc in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
36% less capital invested
Capital invested by funds: $70.6M → $45.4M (-$25.2M)
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$123K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$923 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$101K |
| 2 |
Renaissance Technologies
New York
|
-$44.2K |
| 3 |
Norges Bank
Oslo,
Norway
|
-$29K |
| 4 |
Morgan Stanley
New York
|
-$12K |
| 5 |
Millennium Management
New York
|
-$6.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Fidelity Investments
Boston,
Massachusetts
| $10.2M | +$123K | +32,320 | +0.8% |
|
2
BlackRock
New York
| $7.56M | – | – | – |
|
|
CAM
3
Cormorant Asset Management
Boston,
Massachusetts
| $6.59M | – | – | – |
|
|
AG
4
Artal Group
Luxembourg
| $5.7M | – | – | – |
|
5
Adage Capital Partners
Boston,
Massachusetts
| $5.37M | – | – | – |
|
|
FI
6
Fosun International
Hong Kong,
China
| $5.12M | – | – | – |
|
|
SCM
7
Suvretta Capital Management
New York
| $3.95M | – | – | – |
|
|
OCA
8
Octagon Capital Advisors
New York
| $325K | -$101K | -26,600 | -18% |
|
|
9
Millennium Management
New York
| $272K | -$6.3K | -1,653 | -2% |
|
|
10
Norges Bank
Oslo,
Norway
| $165K | -$29K | -7,604 | -11% |
|
11
Tudor Investment Corp
Stamford,
Connecticut
| $51K | -$4.12K | -1,080 | -5% |
|
|
12
Renaissance Technologies
New York
| $29K | -$44.2K | -11,600 | -51% |
|
|
13
UBS Group
Zurich,
Switzerland
| $1K | +$923 | +242 | New |
|
|
14
Morgan Stanley
New York
| – | -$12K | -2,800 | Closed |
|
15
Bank of America
Charlotte,
North Carolina
| – | -$534 | -140 | -58% |
|
AMAM Hedge Fund Activity: Q2 2022 in Review
14 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q2 2022, worth a combined $45.4M — down 36% from $70.6M a quarter earlier.
Fund positioning in AMAM was balanced in Q2 2022: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 6 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $123K. The largest seller was Octagon Capital Advisors, cutting an estimated $101K.
- 14 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $45.4M of Ambrx Biopharma Inc stock for Q2 2022, down 36% quarter-over-quarter.
- 1 fund opened new Ambrx Biopharma Inc positions in Q2 2022 and 1 closed out, a net change of 0 holders.
- The largest Ambrx Biopharma Inc buyer in Q2 2022 was Fidelity Investments, an estimated $123K added.
- The largest Ambrx Biopharma Inc seller in Q2 2022 was Octagon Capital Advisors, an estimated $101K sold.
Based on aggregated 13F filings for Q2 2022.